Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Invasive Aspergillose der Lunge bei bullösem Pemphigoid.

Koga H, Imamura T, Urae K, Furuta T, Akiba J, Nakama T.

J Dtsch Dermatol Ges. 2019 Oct;17(10):1060-1062. doi: 10.1111/ddg.13947_g. German. No abstract available.

PMID:
31631541
2.

Invasive pulmonary aspergillosis associated with bullous pemphigoid.

Koga H, Imamura T, Urae K, Furuta T, Akiba J, Nakama T.

J Dtsch Dermatol Ges. 2019 Oct;17(10):1060-1062. doi: 10.1111/ddg.13947. Epub 2019 Oct 9. No abstract available.

PMID:
31596531
3.

Identification of GSK3β inhibitor kenpaullone as a temozolomide enhancer against glioblastoma.

Kitabayashi T, Dong Y, Furuta T, Sabit H, Jiapaer S, Zhang J, Zhang G, Hayashi Y, Kobayashi M, Domoto T, Minamoto T, Hirao A, Nakada M.

Sci Rep. 2019 Jul 11;9(1):10049. doi: 10.1038/s41598-019-46454-8.

4.

Juxta-vertebral Lesions Associated with Granulomatosis with Polyangiitis.

Yoshida Y, Kaieda S, Furuta T, Ida H.

Intern Med. 2019 Sep 1;58(17):2587-2588. doi: 10.2169/internalmedicine.2903-19. Epub 2019 May 22. No abstract available.

5.

Case of metastatic glioblastoma with primitive neuronal component to the lung.

Tamai S, Kinoshita M, Sabit H, Furuta T, Miyashita K, Yoshimura K, Homma T, Harada K, Nakada M.

Neuropathology. 2019 Jun;39(3):218-223. doi: 10.1111/neup.12553. Epub 2019 Apr 25.

PMID:
31025405
6.

Expression of GLUT1 in Pseudopalisaded and Perivascular Tumor Cells Is an Independent Prognostic Factor for Patients With Glioblastomas.

Komaki S, Sugita Y, Furuta T, Yamada K, Moritsubo M, Abe H, Akiba J, Miyagi N, Nakamura H, Miyoshi H, Ohshima K, Morioka M.

J Neuropathol Exp Neurol. 2019 May 1;78(5):389-397. doi: 10.1093/jnen/nly124.

7.

Ligand-dependent EphB4 activation serves as an anchoring signal in glioma cells.

Kawahara Y, Furuta T, Sabit H, Tamai S, Dong Y, Jiapaer S, Zhang J, Zhang G, Oishi M, Miyashita K, Hayashi Y, Nakada M.

Cancer Lett. 2019 May 1;449:56-65. doi: 10.1016/j.canlet.2019.02.021. Epub 2019 Feb 15.

PMID:
30776480
8.

Human leukocyte antigen class II expression is a good prognostic factor in adult T-cell leukemia/lymphoma.

Takeuchi M, Miyoshi H, Asano N, Yoshida N, Yamada K, Yanagida E, Moritsubo M, Nakata M, Umeno T, Suzuki T, Komaki S, Muta H, Furuta T, Seto M, Ohshima K.

Haematologica. 2019 Aug;104(8):1626-1632. doi: 10.3324/haematol.2018.205567. Epub 2019 Jan 10.

9.

Malignant progression of an extraventricular neurocytoma arising from the VIIIth cranial nerve: A case report and literature review.

Sugita Y, Furuta T, Komaki S, Ohshima K, Sakata K, Morioka M.

Neuropathology. 2019 Apr;39(2):120-126. doi: 10.1111/neup.12533. Epub 2018 Dec 26. Review.

PMID:
30588667
10.

Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors.

Fukuoka K, Kanemura Y, Shofuda T, Fukushima S, Yamashita S, Narushima D, Kato M, Honda-Kitahara M, Ichikawa H, Kohno T, Sasaki A, Hirato J, Hirose T, Komori T, Satomi K, Yoshida A, Yamasaki K, Nakano Y, Takada A, Nakamura T, Takami H, Matsushita Y, Suzuki T, Nakamura H, Makino K, Sonoda Y, Saito R, Tominaga T, Matsusaka Y, Kobayashi K, Nagane M, Furuta T, Nakada M, Narita Y, Hirose Y, Ohba S, Wada A, Shimizu K, Kurozumi K, Date I, Fukai J, Miyairi Y, Kagawa N, Kawamura A, Yoshida M, Nishida N, Wataya T, Yamaoka M, Tsuyuguchi N, Uda T, Takahashi M, Nakano Y, Akai T, Izumoto S, Nonaka M, Yoshifuji K, Kodama Y, Mano M, Ozawa T, Ramaswamy V, Taylor MD, Ushijima T, Shibui S, Yamasaki M, Arai H, Sakamoto H, Nishikawa R, Ichimura K; Japan Pediatric Molecular Neuro-Oncology Group (JPMNG).

Acta Neuropathol Commun. 2018 Dec 4;6(1):134. doi: 10.1186/s40478-018-0630-1.

11.

Epidemiology and secular trends of malignant lymphoma in Japan: Analysis of 9426 cases according to the World Health Organization classification.

Muto R, Miyoshi H, Sato K, Furuta T, Muta H, Kawamoto K, Yanagida E, Yamada K, Ohshima K.

Cancer Med. 2018 Nov;7(11):5843-5858. doi: 10.1002/cam4.1805. Epub 2018 Oct 11.

12.

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma.

Jiapaer S, Furuta T, Tanaka S, Kitabayashi T, Nakada M.

Neurol Med Chir (Tokyo). 2018 Oct 15;58(10):405-421. doi: 10.2176/nmc.ra.2018-0141. Epub 2018 Sep 21. Review.

13.

RUNX2 Promotes Malignant Progression in Glioma.

Yamada D, Fujikawa K, Kawabe K, Furuta T, Nakada M, Takarada T.

Neurochem Res. 2018 Nov;43(11):2047-2054. doi: 10.1007/s11064-018-2626-4. Epub 2018 Sep 10.

PMID:
30203400
14.

Clinicopathological and genetic association between epithelioid glioblastoma and pleomorphic xanthoastrocytoma.

Furuta T, Miyoshi H, Komaki S, Arakawa F, Morioka M, Ohshima K, Nakada M, Sugita Y.

Neuropathology. 2018 Jun;38(3):218-227. doi: 10.1111/neup.12459. Epub 2018 Mar 13.

PMID:
29532523
15.

Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma.

Sadahiro H, Kang KD, Gibson JT, Minata M, Yu H, Shi J, Chhipa R, Chen Z, Lu S, Simoni Y, Furuta T, Sabit H, Zhang S, Bastola S, Yamaguchi S, Alsheikh H, Komarova S, Wang J, Kim SH, Hambardzumyan D, Lu X, Newell EW, DasGupta B, Nakada M, Lee LJ, Nabors B, Norian LA, Nakano I.

Cancer Res. 2018 Jun 1;78(11):3002-3013. doi: 10.1158/0008-5472.CAN-17-2433. Epub 2018 Mar 12.

16.

Identification of blood biomarkers in glioblastoma by SWATH mass spectrometry and quantitative targeted absolute proteomics.

Miyauchi E, Furuta T, Ohtsuki S, Tachikawa M, Uchida Y, Sabit H, Obuchi W, Baba T, Watanabe M, Terasaki T, Nakada M.

PLoS One. 2018 Mar 7;13(3):e0193799. doi: 10.1371/journal.pone.0193799. eCollection 2018.

17.

Identification of antipsychotic drug fluspirilene as a potential anti-glioma stem cell drug.

Dong Y, Furuta T, Sabit H, Kitabayashi T, Jiapaer S, Kobayashi M, Ino Y, Todo T, Teng L, Hirao A, Zhao SG, Nakada M.

Oncotarget. 2017 Dec 4;8(67):111728-111741. doi: 10.18632/oncotarget.22904. eCollection 2017 Dec 19.

18.

Prognostic factors for histiocytic and dendritic cell neoplasms.

Shimono J, Miyoshi H, Arakawa F, Sato K, Furuta T, Muto R, Yanagida E, Sasaki Y, Kurita D, Kawamoto K, Nagafuji K, Ohshima K.

Oncotarget. 2017 Oct 19;8(58):98723-98732. doi: 10.18632/oncotarget.21920. eCollection 2017 Nov 17.

19.

The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.

Sugita Y, Furuta T, Ohshima K, Komaki S, Miyoshi J, Morioka M, Abe H, Nozawa T, Fujii Y, Takahashi H, Kakita A.

Neuropathology. 2018 Apr;38(2):125-134. doi: 10.1111/neup.12435. Epub 2017 Oct 24.

PMID:
29067721
20.

Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.

Furuta T, Sabit H, Dong Y, Miyashita K, Kinoshita M, Uchiyama N, Hayashi Y, Hayashi Y, Minamoto T, Nakada M.

Oncotarget. 2017 Apr 4;8(14):22811-22824. doi: 10.18632/oncotarget.15206.

Supplemental Content

Loading ...
Support Center